Novo Nordisk Places a High-Stakes Bet on Volume as Price Halving and CagriSema Decision Loom

Novo Nordisk cuts US list prices for Wegovy, Ozempic, and Rybelsus to $675/month from Jan 2027, aiming for volume-driven growth amid FDA decision on CagriSema by end 2026.

Novo Nordisk has taken the knife to its US pricing structure, announcing a radical reduction in list prices for its blockbuster GLP-1 drugs that will effectively halve monthly costs from January 2027. Wegovy, Ozempic and Rybelsus will each cost $675 per month in the US, a move that swaps margin for scale and carries profound implications for the Danish drugmaker's earnings trajectory.

The strategy comes as the company also prepares for what many analysts consider the most consequential regulatory verdict of its recent history: the US Food and Drug Administration's decision on CagriSema, expected before the end of 2026. These two forces — a deliberate price shock and a pivotal pipeline catalyst — are converging to define Novo Nordisk's near-term outlook.

Market recovery gathers pace

Investors have welcomed the clarity on pricing. Shares currently trade at €41.65, having decisively breached the 200-day moving average of €41.01. The stock has climbed roughly 36% from its spring low of €30.25, with the past seven days alone delivering an 8.57% advance. The rebound has been underpinned by a €15 billion Danish kroner share buyback programme that runs until February 2027, creating a technical floor under the equity.

Yet the price action finds itself at a crossroads. The rally has pushed the relative strength index to 66.8 — approaching overbought territory — while the stock remains almost 32% below its 52-week high of €61.20. The 200-day line, historically a resistance level in prolonged downtrends, is now being tested as support.

The margin-for-volume gamble

The core proposition is stark: Novo Nordisk is betting that a dramatic expansion in patient volumes will offset the halving of US list prices. The company needs to broaden its patient base substantially to make the arithmetic work. At $675 per month, the drugs become accessible to a far larger pool of insured and self-pay patients, but the margin compression is real.

Kritiker warn that if the hoped-for patient surge does not materialise, the impact on operating profits could be severe. The company's own guidance for 2026 already projects a decline in adjusted revenue and operating profit growth of minus 4% to minus 12% at constant exchange rates — the first annual top-line contraction in years. Lower realised prices, reduced Medicaid reimbursements and a most-favoured-nation clause in US contracts are all eating into margins. Meanwhile, patent expiries for the semaglutide molecule in certain international markets add a structural headwind that no single product launch can fully neutralise.

CagriSema: the make-or-break pipeline event

If the pricing strategy is about volume, CagriSema is about differentiation. Novo Nordisk has submitted its next-generation amylin-semaqlutide combination to the FDA for approval in obesity and type 2 diabetes. The pivotal REDEFINE-1 study recorded an average weight loss of 22.7%, falling short of the company's internal target of at least 25% and trailing Eli Lilly's Zepbound on direct comparison. However, the broader clinical dataset — including the REIMAGINE-1 and REIMAGINE-2 studies published in The Lancet Diabetes & Endocrinology — suggests CagriSema could secure a dual label covering both adiposity and diabetes. That would dramatically expand its addressable patient pool and justify a premium pricing position.

A positive FDA verdict with a broad label would validate Novo Nordisk's pipeline strategy and give investors a reason to look past the pricing headwinds. A narrow label or a request for additional data would leave the shares exposed to the structural earnings pressures that are already baked into the 2026 guidance.

Competition and pipeline depth

Eli Lilly remains the most immediate threat. Its oral obesity candidate Orforglipron is on track for a European launch as early as the end of 2026, directly challenging Novo Nordisk's newly approved oral Wegovy. The oral Wegovy pill has nonetheless exceeded expectations: first-quarter 2026 revenue reached approximately 2.3 billion Danish kroner, nearly double original forecasts. The UK's Medicines and Healthcare products Regulatory Agency granted approval for the oral formulation on June 11, making it the first orally administered GLP-1 weight-loss product authorised in Britain.

Beyond CagriSema, Novo Nordisk is advancing Zenagamtide — a next-generation GLP-1 and amylin receptor agonist being investigated in both oral and subcutaneous formulations. This asset could extend the company's obesity franchise well into the next decade, provided it clears the clinical and regulatory hurdles ahead.

Technical levels and catalysts to watch

Near-term support rests at the 50-day moving average of €37.51, while the 100-day line at €36.48 marks a deeper safety net should the recovery stall. A sustainable hold above the 200-day average would open the path towards €45, a level that appears achievable if oral Wegovy momentum continues and the buyback absorbs selling pressure.

Investors have two concrete milestones on the horizon. The next quarterly earnings release will reveal whether the 2026 revenue decline lands at the upper or lower end of the minus 4% to minus 12% range — a result closer to minus 4% would bolster the recovery thesis. Beyond that, the FDA's CagriSema verdict looms as the single most important event for the stock's medium-term direction. Until that decision arrives, the share price will oscillate between the support of a massive buyback and the gravity of an unprecedented price cut.